Research programme: metabolic disorders therapeutics - Azafaros
Latest Information Update: 28 Aug 2022
At a glance
- Originator Amsterdam UMC; Leiden University
- Developer Azafaros
- Class Aza compounds; Small molecules
- Mechanism of Action Lipid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Lysosomal storage diseases in Netherlands (PO)
- 14 Jun 2020 Research programme: metabolic disorders therapeutics - Azafaros is available for licensing as of 14 Jun 2020. www.azafaros.com
- 23 Jul 2018 Azafaros in-licenses aza-sugar compounds from Leiden University and Amsterdam UMC before July 2018